Tests a uterine tissue biopsy test to help diagnose endometriosis
Tests a uterine tissue biopsy test to diagnose endometriosis without surgery in adults.
Key facts
- Who runs it
- Hera Biotech, Inc.
- Where
- Corpus Christi, Houston, and Saginaw, United StatesSee the 3 sites
- Trial code
- Registry title
- Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 75 people, planned
- Started
- 14 Sept 2022
- Planned end
- 10 Apr 2023
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MetriDx
- Record updated
- 26 January 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 50 who may have endometriosis, or who are already diagnosed, and will have laparoscopic surgery. A group without endometriosis can also join.
- Age
- 18 to 50 years, inclusive
- Sex
- Women (natural born female of childbearing potential)
- Disease stage
- Cohorts 1 and 2: suspected or previously diagnosed endometriosis, assigned by laparoscopy results. Cohort 3: no suspected endometriosis and no earlier diagnosis or symptoms.
- Earlier treatment
- Must not have had surgery to remove or burn off endometriosis, or treatment such as GnRH, in the past 12 months. Surgical report from an earlier laparoscopy must show endometriosis was not treated that way.
Main reasons for not taking part
- Had a hysterectomy
- Pregnant, breast feeding, or gave birth in the last 6 months
- BMI 40 or above, or taking a blood thinner
- HIV, AIDS, hepatitis A, B or C, or active cancer
- History of uterine fibroids or reproductive cancer
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Able to understand and provide informed consent
- Natural born female of childbearing potential
- Age between 18 and 50, inclusive
- Not pregnant at Visit 0 (screening) or Visit 1 (day of procedure)
- Free of systemic or pelvic disorder that, in the opinion of the investigator, may interfere with the tissue collection procedure, analysis of the tissue or increase the risk to subject
- Must not have received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months
- For Cohort 1 and 2:; Suspected of having endometriosis, or previously diagnosed with endometriosis, and currently recommended for laparoscopic surgery by physician; Must have laparoscopic surgery within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day), or a laparoscopy on record within the 12 months prior to Visit 0 for diagnosis only; Surgical report from prior laparoscopy must indicate that endometriosis was not treated with surgical ablation or excision; Subjects will be assigned to Cohort 1 or 2 based on diagnosis and staging results from laparoscopy
- Or for Cohort 3:; Not suspected of having endometriosis; no previous diagnosis or symptoms of endometriosis, who have had a laparoscopy for another reason, such as tubal ligation or other abdominal procedure, within the past 12 months prior to screening Visit 0,; or laparoscopy to be completed within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day); Surgeon's report must have no supplemental observations of endometriosis lesions or diagnosis. Subjects will be assigned to Cohort 3
Who cannot take part
- Has received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months
- Cohort 3: Prior diagnosis of endometriosis, or surgical note from prior laparoscopy that indicates endometriosis lesions were observed
- Is currently taking a blood thinner medication
- Undergoing fertility or hormone therapy treatments
- Has participated in any interventional clinical trial in the previous 90 days in which an investigational drug was administered
- Surgical history of hysterectomy
- Diagnosed with HIV, AIDS, hepatitis A, B, or C, or has active malignancy
- Has a complicating condition that would pose a hazard to tissue handling
- History of reproductive cancer
- Has a condition that, in the opinion of the investigator, would confound tissue collection or analysis
- Has an active pelvic infection or other infections contra-indicated for laparoscopy
- Has a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past two years
- Younger than 18 or 51 years or older
- Has a BMI 40 or above
- Currently, pregnant, breast feeding, or has given birth in the last 6 months
- History or evidence of uterine fibroids
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in United States
- Corpus Christi Women's CenterCorpus Christi, United StatesContact: Jessica SanchezTaking people
- University of Texas Physician's Women's Center--Memorial CityHouston, United StatesContact: Lori L Wink, MSN, NPTaking people
- Valley OB-GYN Clinic, PCSaginaw, United StatesContact: Mackenzie RittenbergNot yet recruiting
About the trial
What the trial wants to find out
This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.
The 3 groups in the trial
- Cohort 1Existing treatment, for comparison
Endometriosis diagnosed at stage 1 or 2
Treatment: MetriDx
- Cohort 2Existing treatment, for comparison
Endometriosis diagnosed at stage 3 or 4
Treatment: MetriDx
- Cohort 3Other group
Control--Not suspected of having and absence of endometriosis confirmed by diagnostic test. This group has uterine tissue biopsy and laparoscopy for non-endometriosis indication, i.e. tubal ligation
Treatment: MetriDx
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Proof-of-Concept, Obs Study to Evaluate Accuracy of MetriDx Lab Developed Test (LDT) to Accurately Identify Endometriosis-specific Biological Markers Using Micro-fluidic Analysis of Cells Enabling Clinicians to Diagnose Endometriosis
- Plain-language title
- Tests a uterine tissue biopsy test to help diagnose endometriosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05698212, who can take part
- Record updated
- 26 January 2023